Document Detail


Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.
MedLine Citation:
PMID:  12652325     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We describe two cases of intracoronary vascular brachytherapy where bivalirudin (Angiomax), employed as an anticoagulant, led to abrupt vessel closure or threatened abrupt closure. Use of bivalirudin (Angiomax) during intracoronary brachytherapy may predispose to the formation of intracoronary thrombus, related to the reversible binding kinetics of the bivalirudin to thrombin, and resulting in recovery of thrombin functional activity during periods of prolonged stasis that occur during intracoronary brachytherapy. Intracoronary abciximab administration may be a useful strategy in resolving the acute closure, since abciximab administered early during the formation of thrombus has been shown to facilitate clot lysis.
Authors:
Sanjiv Sharma; Brijesh Bhambi; William Nyitray; Kirit Desai; Dean L Davis; Geetanjali Sharma; Pankaj Shukla; Carla File; Tetsuo Ishimori
Related Documents :
21836505 - Induced abortion and adolescent mental health.
21893935 - Perinatal selective serotonin reuptake inhibitor exposure: impact on brain development ...
13833485 - Acute appendicitis complicating pregnancy.
3214385 - Acute fatty liver of pregnancy: clinical features and diagnosis.
8731445 - Age-independent assessment of abnormal fetal growth in the third trimester.
3131725 - Apolipoprotein a-1 in umbilical cord blood of newborn infants: relation to gestational ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  8     ISSN:  1074-2484     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-24     Completed Date:  2003-07-15     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  9-15     Citation Subset:  IM    
Affiliation:
Central Cardiology Medical Clinic, Bakersfield, CA 93301, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Antibodies, Monoclonal / therapeutic use
Brachytherapy*
Coronary Angiography
Coronary Restenosis / drug therapy,  etiology*,  prevention & control
Coronary Vessels / physiopathology*
Female
Hirudin Therapy / adverse effects*
Hirudins / adverse effects*,  analogs & derivatives*
Humans
Immunoglobulin Fab Fragments / therapeutic use
Injections
Male
Middle Aged
Peptide Fragments / adverse effects*,  therapeutic use
Recombinant Proteins / adverse effects*,  therapeutic use
Thrombin / antagonists & inhibitors*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Hirudins; 0/Immunoglobulin Fab Fragments; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 143653-53-6/abciximab; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ventricular fibrillation resulting from acute right ventricular infarction from isolated occlusion o...
Next Document:  Left ventricular performance during acute rate control in atrial fibrillation: the importance of hea...